0
0
12/22/23 at 6:45pm
Organization
Multiple Sclerosis News Today
35 words
0
Comments
In the study, researchers studied whether Ocrevus, which target B-cells, could reduce meningeal inflammation and damage to gray matter.
You are the first to view
https://multiplesclerosisnewstoday.com/news-posts/2023/12/22/ocrevus-failed-lower-ms-inflammation-meninges-pilot-trial/
Create an account
or login to join the discussion